title stringlengths 1 1.19k | keywords stringlengths 0 668 | concept stringlengths 0 909 | paragraph stringlengths 0 61.8k | PMID stringlengths 10 11 |
|---|---|---|---|---|
3.6. Effects of NSDs on Variables at Week 12, as Analyzed by a Multiple Linear Regression | PMC10574690 | |||
3.6.1. Body Composition, Physical Performance, and Nutritional Status | As shown in | PMC10574690 | ||
3.7. Odds Ratio (OR) | NSD | ZINC DEFICIENCY, ASMI | Crude ORs are shown in However, the risk of a low ASMI increased after the NSD intervention in models 1 and 2. After adjusting for the baseline ASMI and other parameters in model 2, the risk of a low ASMI disappeared in model 3. Therefore, it was estimated that the higher risk of a low ASMI might be related to the sign... | PMC10574690 |
3.8. QOL and SF-36 Questionnaire | PMC10574690 | |||
3.8.1. Effects of the NSD or NE Interventions | MH | After 12 weeks of the intervention, the NSD group exhibited significant improvements in physical function (PF), vitality (VT), mental health (MH), and also the total score of physical health (physical component score, PCS) and total mental health (mental component score, MCS) in the SF-36 questionnaire ( | PMC10574690 | |
3.8.2. Changes in SF-36 Questionnaire Scores after the NSD and NE Interventions | MH, NSD | To evaluate changes and improvements in SF-36 scores after the intervention, we compared changes in scores of both groups by analyzing values of week 12 minus those of week 0. The NSD group had significantly greater improvements in PF, VT, social functioning (SF), MH, PCS, and MCS than the NE group ( | PMC10574690 | |
3.9. Correlations among the SF-36 Questionnaire, the Nutritional Status, Physical Performance, Vit. D, and the Intervention | As shown in | PMC10574690 | ||
4. Discussion | PMC10574690 | |||
4.1. ONSs, BW, Body Composition, and Physical Performance | NSD, NSDs | ASMI | The current results demonstrated that NSDs significantly increased BW and BMI (In this study, the SOF significantly decreased, and walking speed significantly increased without changing the body fat or muscle mass in the NSD group (Compared to participants who only received the NE intervention, the improved effects of ... | PMC10574690 |
4.2. Effects of the NSD on Related Variables | NSDs | REGRESSION | Based on a multiple linear regression, NSDs showed positive effects on BW, BMI, calf circumference, walking speed, and MNA-SF scores, and negative effects on the SOF, and produced an improvement in frailty ( | PMC10574690 |
4.3. Blood Albumin Levels and Related Variables | NSD | BLOOD | Blood albumin levels remained within the normal range in both the NSD and NE groups, although it had significantly decreased in the NSD group after 3 months ( | PMC10574690 |
4.4. Vit. D and Zn Deficiencies | In this study, the definition of the Vit. D status was based on recommendations from the Endocrine Society Task Force on Vitamin D in the US population [The percentage of participants with a Zn deficiency was 37.3% (40/107) at the baseline in this study ( | PMC10574690 | ||
4.5. Crude and Adjusted ORs | NSD | MALNUTRITION | The crude and adjusted ORs showed risks of frailty, malnutrition, and low walking speed were significantly reduced after the NSD intervention ( | PMC10574690 |
4.6. Nutritional Status and QoL | NSDs | Results indicated that NSDs can improve the activity and mental health of older nursing home-dwelling persons more than those who only received NE ( | PMC10574690 | |
4.7. Strengths and Limitations | In this study, the statistical power was 0.99, which indicates a high possibility of identifying a true effect. Additionally, several nursing homes participated in the study. However, some limitations of this study should be addressed. First, the study was conducted between November 2021 and March 2023, when Taiwan was... | PMC10574690 | ||
5. Conclusions | NSD, malnutrition | MALNUTRITION | Current results indicated that the NSD intervention combined with NE for 12 weeks improved the nutritional status, including BW, BMI, and MNA-SF scores, as well as physical performance such as walking speed in the older population at risk of malnutrition ( | PMC10574690 |
Supplementary Materials | The following supporting information can be downloaded at: Click here for additional data file. | PMC10574690 | ||
Author Contributions | Conceptualization, S.-C.Y.; methodology, S.-C.Y. and J.-R.C.; validation, Y.-H.C., S.-C.Y. and J.-R.C.; analysis and interpretation of data, Y.-H.C. and C.-Y.L.; investigation, C.-Y.L., M.-Y.D. and F.-Q.L.; resources, S.-C.Y. and C.-Y.L.; data curation, Y.-H.C. and C.-Y.L.; writing—original draft preparation, Y.-H.C. a... | PMC10574690 | ||
Institutional Review Board Statement | The study was conducted in accordance with the Declaration of Helsinki. The study protocol was approved by the Taipei Medical University (TMU)-Joint Institutional Review Board (ID: N202011065, 27 January 2021) and ClinicalTrials.gov Protocol Registration and Results System (NCT04857463) “ | PMC10574690 | ||
Informed Consent Statement | Informed consent was obtained from all subjects involved in the study. | PMC10574690 | ||
Data Availability Statement | Data available on request due to privacy/ethical restrictions. | PMC10574690 | ||
Conflicts of Interest | The authors declare no conflict of interest. | PMC10574690 | ||
References | Malnutrition, NSD, appendicular skeletal muscle, malnutrition | OSTEOPOROTIC FRACTURE, MOS, MALNUTRITION, ASMI, MALNUTRITION, REGRESSION | Study flow diagram for nutritional supplement drink or nutritional education on the nutritional status in older individuals at risk of malnutrition. MUST, Malnutrition Universal Screening Tool.Beneficial effects of a nutritional supplement drink (NSD) on the nutritional status of older individuals at high risk of malnu... | PMC10574690 |
Methods: | treatment-emergent adverse, Attention-Deficit/Hyperactivity Disorder | In this study, a 5-week, open-label dose-optimization period (DOP) preceded a 2-week, randomized, crossover double-blind treatment period (DBP). Eligible patients received d-ATS 5 mg during the DOP, with weekly evaluations for increase to 10, 15, and 20 mg (equivalent to labeled doses of 4.5, 9, 13.5, and 18 mg/9 hours... | PMC10282809 | |
Results: | In total, 110 patients entered the DOP, with 106 patients randomized (DBP). During the DBP, the least-squares mean (95% confidence interval) difference for d-ATS versus placebo in ADHD-RS-IV total score was −13.1 (−16.2 to −10.0; | PMC10282809 | ||
Conclusions: | ADHD | SECONDARY | d-ATS was effective in treating ADHD in children and adolescents, meeting all secondary endpoints, with a large effect size and NNT of 2–3 to achieve a clinically meaningful response. d-ATS was safe and well tolerated, with minimal dermal reactions. | PMC10282809 |
Clinical Trial Registration: | NCT01711021. | PMC10282809 | ||
Introduction | Psychiatric, Attention-deficit/hyperactivity disorder, hyperactivity/impulsivity, Attention Deficit/Hyperactivity Disorder, ADHD, neurodevelopmental disorder | DIFFICULTY SWALLOWING, SECONDARY | Attention-deficit/hyperactivity disorder (ADHD) is a chronic neurodevelopmental disorder characterized by persistent inattention and/or hyperactivity/impulsivity that interferes with function or development and negatively impacts social, academic, and occupational activities (American Psychiatric Association, 2013; Bél... | PMC10282809 |
Methods | PMC10282809 | |||
Patients and study design | UC | The study described herein was approved by the Western Institutional Review Board and the UC Irvine Institutional Review Board. This study included a 5-week, open-label dose-optimization period (DOP) followed by a 2-week, randomized, crossover double-blind treatment period (DBP), with details reported previously (Cutle... | PMC10282809 | |
Study assessments | ADVERSE EVENTS, SECONDARY | Secondary objectives for this study included assessment of efficacy through the ADHD-RS-IV scale, CPRS-R:S scale, and CGI-I and CGI-S scores. Analysis of these secondary assessments was performed on the Full Analysis Set, which included all randomized patients who received at least one dose of study medication.Safety o... | PMC10282809 | |
Statistical analysis | hyperactivity, impulsivity | LS means, 95% CIs, and Model-based LS mean effect sizes were assessed for ADHD-RS-IV total score and the inattention and hyperactivity–impulsivity subscale scores NNT was calculated | PMC10282809 | |
Results | PMC10282809 | |||
Baseline characteristics | In total, 110 subjects were enrolled in the DOP, with optimized doses achieved for 107 patients. The Details of the demographics and baseline characteristics for the population have been reported in detail previously. Briefly, 69% of patients were male, and weight, height, and body mass index were balanced across treat... | PMC10282809 | ||
Safety | Safety outcomes have been reported in detail previously (Cutler et al., | PMC10282809 | ||
Discussion | ADHD | SECONDARY | The reported data indicate that d-ATS was effective in the treatment of ADHD in children and adolescents, meeting all secondary endpoints. Throughout the DOP, treatment with d-ATS resulted in consistent improvement as measured by ADHD-RS-IV score, with a significant improvement versus placebo observed during the DBP. A... | PMC10282809 |
Conclusion | ADHD | d-ATS represents an important innovation for the known population of patients with ADHD who respond better to amphetamine than methylphenidate (Arnold, | PMC10282809 | |
Clinical Significance | ADHD | NERVOUS SYSTEM DISORDERS | Methylphenidate and amphetamines have shown high efficacy in treating ADHD in children and adolescents; however, approximately 40% of patients with ADHD respond to only one of these drugs, indicating the need for additional treatment options, including multiple formulations. Although transdermal therapies have numerous... | PMC10282809 |
Acknowledgments | The authors thank Michelle Jones, PhD, MWC and Anthony DiLauro, PhD of PharmaWrite, LLC, for medical writing and editorial assistance, which were funded by Noven Pharmaceuticals, Inc. This article was prepared according to the International Society for Medical Publication Professionals' “Good Publication Practice for C... | PMC10282809 | ||
Authors' Contributions | All authors were actively involved in study design, data acquisition, or data analysis/interpretation, and in drafting or critically revising the article. All authors reviewed the final article and gave approval for submission. | PMC10282809 | ||
Disclosures | A.J.C. reports personal fees from AbbVie, Acadia, Alfasigma, Alkermes, Attentive, Corium, Intracellular Therapies, Ironshore, Janssen, Lundbeck, MedAvante-ProPhase, Neurocrine, Neuroscience Education Institute, Noven, Sunovion, Takeda, and Teva; grants from Arbor, Axsome, Biohaven, KemPharm, Novartis, and Purdue; grant... | PMC10282809 | ||
References | PMC10282809 | |||
Purpose | chronic open-angle glaucoma, OAG | This study aims to evaluate whether the use of citicoline oral solution could improve quality of life in patients with chronic open-angle glaucoma (OAG). | PMC10199108 | |
Design | Randomized, double-masked, placebo-controlled, cross-over study was used. Patients were randomized to one of the two sequences: either citicoline 500 mg/day oral solution-placebo or placebo-citicoline 500 mg/day oral solution. Switch of treatments was done after 3 months; patients were then followed for other 6 months.... | PMC10199108 | ||
Outcomes | The primary outcome was the mean change of “intra-patient” composite score of the Visual Function Questionnaire-25 (VFQ-25) | PMC10199108 | ||
Methods | visual field damage, OAG | EYE | The trial was multicenter, conducted at 5 European Eye Clinics. OAG patients with bilateral visual field damage, a mean deviation (MD) ranging from − 5 to − 13 dB in the better eye, and controlled IOP were included. VFQ-25 and SF-36 questionnaires were administered at baseline and at 3-, 6-, and 9-month visits. A mixed... | PMC10199108 |
Results | The primary pre-specified outcome of the analysis reached statistical significance ( | PMC10199108 | ||
Conclusions | glaucomatous | This is the first placebo-controlled clinical study evaluating the effect of a medical treatment aiming at improving vision-related quality of life in glaucomatous patients. | PMC10199108 | |
Supplementary Information | The online version contains supplementary material available at 10.1007/s00417-022-05947-5. | PMC10199108 | ||
Keywords | Open access funding provided by Università degli Studi di Milano within the CRUI-CARE Agreement.
| PMC10199108 | ||
Introduction | Open-angle glaucoma, senile dementia, OAG | PROGRESSIVE OPTIC NEUROPATHY, BLINDNESS, DISEASE, SENILE DEMENTIA, NEURODEGENERATIVE DISEASES, OPEN-ANGLE GLAUCOMA, VISUAL IMPAIRMENT | Open-angle glaucoma (OAG) is a progressive optic neuropathy and one major cause of global blindness [Visual impairment is commonly associated with the disease, particularly with more advanced stages [Treatment of the disease has the objective of slowing (or stopping) progression of damage to maintain vision-related qua... | PMC10199108 |
Methods | -11, EYE | The trial was conducted at 5 University Eye Clinics in Rome, Barcelona, Leuven, Thessaloniki, and Milan between winter 2019 and summer 2021. The study was designed following the tenets of the Declaration of Helsinki, and the protocol was submitted and approved by each University Ethics Committee. The trial was funded b... | PMC10199108 | |
Patients in the trial | VF, pigmentary glaucomas, glaucomatous, visual field damage, stroke, pseudoexfoliative, dementia, Parkinson’s disease, Glaucoma, OAG, glaucoma, glaucomatous damage, VF damage | PIGMENTARY GLAUCOMA, STROKE, OPTIC NERVE, GLAUCOMA, GLAUCOMA | Glaucoma definition was based on VF damage (24–2 SITA standard strategy, Humphrey Visual Field Analyser, HFA) corresponding to glaucomatous changes at the optic nerve head (ONH) irrespective of IOP. Inclusion criteria were patients with OAG, including pseudoexfoliative and pigmentary glaucomas; age ≥ 18 years; presence... | PMC10199108 |
Study design | VF | TREATMENT SIDE EFFECTS, LENS | The trial was a randomized, double-masked, placebo-controlled, cross-over study. Patients who accepted to participate in the trial signed an informed consent form and were randomized to one of the two sequences of the cross-over design: either citicoline 50 mg/ml oral solution-placebo or placebo-citicoline 50 mg/ml ora... | PMC10199108 |
Study treatments | Neurotidine® | DISEASE | Patients were treated with any IOP-lowering agent to control the disease. Patients were randomized to a citicoline 50 mg/ml oral solution-placebo or placebo-citicoline 50 mg/ml oral solution sequence and received treatment for 3 months in the first period and for 6 months in the second period of the cross-over design. ... | PMC10199108 |
Study outcomes | The primary outcome was the mean change of “intra-patient” global score of the VFQ-25 questionnaire after citicoline oral solution vs placebo at 6 months as compared with baseline. Secondary outcomes were the difference in the change from baseline at 3 and 9 months; the comparison between different time-points in each ... | PMC10199108 | ||
Analysis | The trial sample size was calculated on the main outcome of the study. With a sample size in each sequence group of 100 (a total sample size of 200), a 2 × 2 crossover design would have 80% power to detect a difference in mean intra-patients global score of 3.0 assuming that the crossover ANOVA √MSE is 10.607 (the stan... | PMC10199108 | ||
Results | INTRAOCULAR PRESSURE | One-hundred-fifty-five patients were included in the study. Four patients were excluded because not properly randomised. Four patients from the citicoline oral solution-placebo arm and one from the placebo-citicoline oral solution arm were excluded because they did not complete any visit beyond the baseline, as reporte... | PMC10199108 | |
Discussion | glaucomatous, VF damage, glaucoma | DISEASE, RECRUITMENT, NEURODEGENERATIVE DISEASES, SECONDARY, GLAUCOMA | This is the first placebo-controlled clinical study evaluating the effect of a medical treatment aiming at improving vision-related QoL in glaucomatous patients. The primary pre-specified outcome of the analysis (difference in the change from baseline at six months) reached statistical significance (Citicoline oral sol... | PMC10199108 |
Funding | Open access funding provided by Università degli Studi di Milano within the CRUI-CARE Agreement. The trial was funded by Omikron Italia, and registered (NCT04046809, clinicaltrials.gov). | PMC10199108 | ||
Declarations | PMC10199108 | |||
Ethics approval | All procedures performed in studies involving human participants were in accordance with the ethical standards of the Ethics Committee of each University involved in the trial, and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with... | PMC10199108 | ||
Conflict of interest
| LR, FG, GM, IS, FT, and GM are consultants for Omikron Italia srl. | PMC10199108 | ||
References | PMC10199108 | |||
2. Materials and Methods | paresis of the upper extremities, Stroke, stroke, ischemic stroke, dizziness, motor impairment, febrile | STROKE, STROKE, ISCHEMIC STROKE | The double-blind, randomized, placebo-control research was conducted at the Clinic for Rehabilitation “Dr. Miroslav Zotovic” in Belgrade over three years from March 2019 to March 2022. The design of this study was the double-blind because neither patients nor the data collectors know which treatment the patients were r... | PMC9958781 |
2.1. Sample Size | To determine the needed sample size, a two-tailed independent | PMC9958781 | ||
2.2. Interventions | The patients were allocated randomly into two groups using 60 sequentially numbered, opaque, sealed envelopes that had been prepared earlier using a computerized table of random numbers (using RSudio), and which were balanced to ensure equal numbers in each group. The allocations were concealed from the statistician un... | PMC9958781 | ||
2.3. Safety Criteria | ADVERSE EFFECTS | The rehabilitation protocol was carried out individually for all patients under the supervision of a physio and occupational therapist with a graduate degree and vast experience in neurological rehabilitation. Clinicians had performed laboratory tests and medical evaluations at the beginning of the study, and at least ... | PMC9958781 | |
2.4. Outcome Measures | sensory loss, dysarthria, neurological disease, Stroke, stroke, ataxia, upper extremity motor impairment, visual-field loss | STROKE, NEUROLOGICAL DISEASE, STROKE | Stroke severity was recorded using the NIHSS through 15 items on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. Items were scored on a 3- to 5-point scale, with a maximum total score of 42 points. According to the NIHSS, str... | PMC9958781 |
2.5. Statistical Analysis | To test for the effects of Cerebrolysin across all time points (pre-therapy, post-therapy, and after 90 days), we used a two-way repeated measures analysis of variance (ANOVA) with time and groups as the within-patient factor and the between-patient factor, respectively, when the conditions were fulfilled. Otherwise, a... | PMC9958781 | ||
3. Results | post-stroke hemiparesis | ADVERSE EVENTS | One hundred and twelve patients with severe post-stroke hemiparesis were screened for eligibility criteria. Sixty patients fulfilled all eligibility criteria. Twenty-seven did not meet the inclusion criteria, thirteen patients were medically unstable, and twelve declined to participate in the clinical trial. There were... | PMC9958781 |
4. Discussion | subacute stroke stage, post-stroke, upper extremity motor impairment, motor impairment, acute ischemic stroke, sub-acute stroke | The present study aimed to investigate the effects of a three-week intravenous administration of Cerebrolysin added to the conventional rehabilitation treatment of patients at the early stage of severe sub-acute stroke compared to rehabilitation treatment only. This study’s results have shown that adding Cerebrolysin r... | PMC9958781 | |
Study Limitations | cognitive and social status | ADVERSE EFFECTS, DISEASE | Several limitations should be considered when interpreting the results of this study. We did not consider factors that can affect the rehabilitation outcome, such as the side and localization of the lesion, motor network plasticity using functional neuroimaging, the presence of comorbidities, or the patient’s cognitive... | PMC9958781 |
Author Contributions | Conceived and designed the experiments: S.Z.M., L.M.K., O.C.D. Performed the experiments: S.Z.M., O.C.D., S.D.-D., L.M.K. Analyzed the data: V.M.J., S.Z.M., L.M.K., and O.C.D. Prepared graphic representation of data: V.M.J. Contributed reagents/materials/analysis tools: S.Z.M., O.C.D., S.D.-D., L.M.K. Wrote the paper: ... | PMC9958781 | ||
Institutional Review Board Statement | The study was conducted according to the guidelines of the Declaration of Helsinki. The Ethics Committee of the Clinic for rehabilitation “Dr. Miroslav Zotović” approved this study (No.03-1518, 12 September 2016). | PMC9958781 | ||
Informed Consent Statement | Informed consent was obtained from all subjects involved in the study. | PMC9958781 | ||
Data Availability Statement | The data that support the findings of this study can be found in the medical system of the Clinic for rehabilitation “Dr. Miroslav Zotović” and are available from the corresponding author upon reasonable request. | PMC9958781 | ||
Conflicts of Interest | The authors declare that they have no conflicts of interest. | PMC9958781 | ||
References | Stroke | RECRUITMENT, STROKE | Flow diagram of patient recruitment.The interaction effect between time and therapy in NIHSS, FMA-UE, BI, and ARAT. The Y-axis represents mean values with error bars. The X-axis represents time points pre, post, and after 90 days.The changes in the outcome measures over time for NIHSS, BI, FMA-UE and ARAT in the Cerebr... | PMC9958781 |
Background | hypertension | HYPERTENSION | Nighttime blood pressure (BP) and an abnormal nocturnal BP dipping profile are important cardiovascular risk factors in patients with hypertension. This post hoc analysis investigated the effects of sacubitril/valsartan on 24‐hour BP in patients with mild‐to‐moderate hypertension and in patient subgroups based on noctu... | PMC10227270 |
Methods and Results | −7.3, hypertension, 24‐hour | HYPERTENSION | Data from a randomized clinical trial comparing the BP‐lowering effects of 8 weeks of treatment with sacubitril/valsartan (200 or 400 mg/d) and olmesartan (20 mg/d) in Japanese patients with mild‐to‐moderate hypertension were analyzed. The primary end point was change in 24‐hour, daytime, and nighttime BP in patient su... | PMC10227270 |
Conclusions | HYPERTENSION | This analysis highlights the value of sacubitril/valsartan therapy in patients with a nondipper profile of nocturnal BP and confirms this agent's potent 24‐hour BP‐lowering effect in Japanese populations with hypertension. | PMC10227270 | |
Registration | URL: | PMC10227270 | ||
Subject Categories | Supplemental Material is available at For Sources of Funding and Disclosures, see page 10. | PMC10227270 | ||
Nonstandard Abbreviations and Acronyms | diastolic blood pressuresystolic blood pressure
| PMC10227270 | ||
Clinical Perspective | PMC10227270 | |||
What Is New? | Nondipper |
These are the first data on the differential 24‐hour blood pressure (BP)‐lowering effects of sacubitril/valsartan in patient subgroups based on the nocturnal BP dipping profile.Nondipper patients showed the most significant decreases in ambulatory BP (especially nighttime BP) during sacubitril/valsartan versus olmesar... | PMC10227270 | |
What Are the Clinical Implications? | hypertension, cardiovascular disease | EVENTS, HYPERTENSION, CARDIOVASCULAR DISEASE, BLIND |
Given the contribution of nighttime BP and an abnormal nocturnal BP dipper pattern to cardiovascular risk, treatment with sacubitril/valsartan impacts multiple mechanisms that could improve cardiovascular outcomes in patients with hypertension.A substantial body of evidence shows that nocturnal hypertension is a signi... | PMC10227270 |
METHODS | PMC10227270 | |||
Study Design | ESSENTIAL HYPERTENSION | The data that support the findings of this study are available from Novartis AG upon reasonable request.This post hoc analysis used data from a multicenter, randomized, double‐blind, parallel‐group study comparing the BP‐lowering effects of sacubitril/valsartan and olmesartan in Japanese patients with mild‐to‐moderate ... | PMC10227270 | |
Study Participants | Nondipper | Full details of patient inclusion and exclusion criteria have been reported previously.Dipper: mean nighttime (10 Nondipper: mean nighttime ambulatory BP fall of <10% versus daytime ambulatory BP | PMC10227270 | |
Study Procedures and Treatments | There was a 2‐ to 4‐week single‐blind, placebo run‐in period at baseline. The run‐in period for previously treated patients was 3 to 4 weeks, during which all existing antihypertensive therapy was tapered and discontinued, and the run‐in period for previously untreated patients was 2 weeks. After the run‐in period, pat... | PMC10227270 | ||
Clinical End Points | The primary end point for this analysis was the change in 24‐hour, daytime, and nighttime BP from baseline to 8 weeks in patient subgroups based on nocturnal BP dipping status (dipper and nondipper). Secondary end points included the following: change from baseline to 8 weeks in 24‐hour BP; change from baseline to 8 we... | PMC10227270 | ||
Follow‐Up and Assessments | Ambulatory BP measurement over 24 hours was conducted at 2 time points in a subset of participants in the original study. The first 24‐hour ambulatory BP measurement was performed after a patient had qualified for randomization based on office BP measurement but before administering the first dose of double‐blind study... | PMC10227270 | ||
Statistical Analysis | SECONDARY | The analysis population included patients with ambulatory BP data at baseline and all follow‐up visits. Demographics and baseline characteristics are presented using descriptive statistics, including mean±standard deviation, minimum, first quartile, median, third quartile, and maximum values for continuous variables, a... | PMC10227270 | |
RESULTS | PMC10227270 | |||
Study Population | HYPERTENSION | Of the full analysis set from the randomized trial (n=1161), 632 patients (54% in total, 56% treated with sacubitril/valsartan 200 and 400 mg/d and 51% treated with olmesartan) had ambulatory BP data at baseline and follow‐up and were included in this analysis (Patient Demographics and Clinical Characteristics at Basel... | PMC10227270 | |
Overall Change in Ambulatory | Changes in 24‐hour, daytime, and nighttime ambulatory SBP and DBP from baseline to week 8 were more significant with both dosages of sacubitril/valsartan compared with olmesartan (Figure | PMC10227270 | ||
Change in ambulatory systolic blood pressure (A) and diastolic blood pressure (B) from baseline to week 8. | Data are least‐squares mean change±standard error (repeated measures ANCOVA model). Daytime: 6 | PMC10227270 | ||
Change in Ambulatory | Significant reductions in 24‐hour, daytime, and nighttime SBP and DBP from baseline to week 8 were seen during treatment with sacubitril/valsartan 200 and 400 mg/d and olmesartan 20 mg/d in both the dipper and nondipper groups (Figure | PMC10227270 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.